Patrick McNamara Named Chief Commercial Officer at Yunu, Driving Growth in Trial Imaging for Pharma
CARY, NC / ACCESS Newswire / June 24, 2025 / Yunu, the creator and leader in cloud-native imaging workflows for clinical trials, proudly announces Patrick McNamara as its new Chief Commercial Officer. With over two decades of experience in clinical research and business development, McNamara has played a pivotal role in Yunu's rapid expansion across the pharmaceutical, biotech, and contract research organization (CRO) sectors.
McNamara's appointment reinforces Yunu's commitment to advancing transformative clinical trial imaging solutions at scale. His deep industry knowledge is built upon years of hands-on leadership as the prior VP of Business Development for the clinical endpoint division of a major CRO as well as key oversight of commercial and operational teams. His extensive experience and strategic vision accelerate Yunu's ability to deeply engage with sponsors and CROs in Yunu's industry-wide effort to transform trialimaging workflows, accelerate new therapies, and improve data quality.
"We are thrilled to appoint Patrick McNamara as our Chief Commercial Officer," said Jeff Sorenson, CEO & Co-founder of Yunu. "Patrick's unique perspective allows Yunu to orient our teams around the specific needs and processes of pharma while also fine-tuning our go-to-market as we continue to deliver game-changing trial acceleration and transparency."
Yunu recently unveiled a groundbreaking software release that empowers pharma sponsors to rapidly configure new studies, connect to readers, and ensure real time access to their imaging data within their primary data systems. This advancement underscores Yunu's role as an innovator and leader in harmonizing multi-site trials, reducing complexity, and accelerating trial imaging timelines.
Yunu is also managing all imaging endpoints delivered to sponsors at more than 25% of NCI-designated Comprehensive Cancer Centers. The platform's impact will be discussed during a special session with City of Hope leadership in addition to showcasing these latest advancements during the 17th Annual AACI CRI Meeting in Chicago from Monday, June 23rd, to Wednesday, June 25th.
ABOUT YUNUYunu enables life sciences organizations to streamline imaging workflows, improve accuracy, and accelerate timelines. Yunu's platform supports clinical trials across various therapeutic areas, offering scalability and flexibility for organizations of all sizes. For more information, visit yunu.io and follow us on LinkedIn or X @Yunu_Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
17 hours ago
- Associated Press
Marin Biologic Laboratories Releases FDA-Ready Bioanalytical Cell-Based Assays White Paper
New Publication Sets Standard for Phase-Appropriate Assay Qualification, Offering Clear Path from IND to Commercialization 'Whether you're preparing for your first IND or scaling up for commercial release, assay integrity is non-negotiable. This white paper reflects our commitment to excellence.'— Tania Weiss, Ph.D., CEO, Marin Biologic Laboratories NOVATO, CA, UNITED STATES, June 27, 2025 / / -- Marin Biologic Laboratories Inc. (MarinBio), a leading bioanalytical testing and regulatory compliance contract research organization (CRO) based in Northern California, announces the release of a new white paper, 'Selecting Bioanalytical Assays for FDA Approved Clinical Trials and Commercialization.' company/selecting-bioanalytical-assays-fda-clinical-trials-commercialization/ This in-depth publication offers the biopharmaceutical industry a clear, scientifically grounded roadmap for selecting regulatory-ready assays that meet FDA requirements. The white paper walks readers through the full continuum of assay development—from early-stage, fit-for-purpose qualified assays to fully validated, GMP-compliant platforms ready for BLA and NDA submission, and commercialization. 'Whether you're preparing for your first IND or scaling up for commercial release, assay integrity is non-negotiable,' said Tania Weiss, Ph.D., CEO of Marin Biologic Laboratories. 'This white paper reflects our commitment to excellence—scientific, operational, and regulatory—and our desire to enable clients to meet FDA expectations without unnecessary delays or cost overruns. Our goal has always been to act as a true scientific partner to our clients, including those pioneering the next generation of therapeutics. This white paper is a natural extension of that mission. We are codifying three decades of experience to provide the entire industry with a clear, actionable framework for navigating the immense complexities of modern drug development. We believe that sharing our expertise in regulatory strategy and advanced bioanalysis will help accelerate innovation across the board.' The white paper content leverages MarinBio's 30 years of scientific leadership and impeccable regulatory track record to enable companies on their journey from preclinical projects to commercialization. The publication draws upon MarinBio's deep expertise in GMP/GLP-compliant assay development and its recent successes in passing both FDA, with no 483s, and EU regulatory audits. Key insights from the white paper include: - Phase 1: Research-Level Assay Development – Streamlined approaches for initial technology transfer or de novo assay design that deliver reliable, fit-for-purpose data for preclinical and early clinical studies. - Phase 2: Assay Qualification – Criteria for building a qualified assay for Phase 2 FDA submissions including intermediate precision, accuracy, linearity, and specificity to support IND-enabling studies with confidence. - Phase 3 & Commercial: GMP Assay Validation – A guideline for validating, and documenting robust assays in full compliance with GLP/GMP and FDA standards—ready for commercial deployment. The white paper also offers real-world advice for biotech and pharma clients navigating pre-IND/IND readiness and BLA/NDA submissions and commercialization phase —making it an essential read for development teams, regulatory leads, and scientific executives. About Marin Biologic Laboratories Inc. Marin Biologic Laboratories (MarinBio) is a woman-owned contract research organization (CRO) with over 30 years of experience supporting the pharmaceutical and biotech sectors. Specializing in custom cell-based assays, GMP/GLP compliance, and regulatory strategy, MarinBio partners with clients to advance therapeutics from discovery to commercialization. With a team of senior PhD scientists and a flawless regulatory audit history, MarinBio provides the scientific expertise and quality systems necessary to meet global compliance standards. Marin Biologic Laboratories is recognized for its scientific agility, rigorous quality systems, and deep understanding of FDA regulatory expectations. The company is known for working collaboratively with clients, ensuring each assay is customized to meet specific regulatory, technical, and commercial goals. Operating from a GMP-compliant facility in Novato, CA, MarinBio supports US and international clients ranging from venture-backed startups to top-tier global biopharma firms. The company's service portfolio includes: - Potency Assays for Lot Release - Stability Testing - PK/PD & Immunogenicity Studies (ADA) - ELISA, Flow Cytometry - Cell-Based Assays ( ) - Molecular Biology - qPCR - GMP / GLP Compliant Validation and Regulatory Reporting For the complete white paper or to discuss your bioanalytical assay development needs, please visit the MarinBio website at Tania L. Weiss, Ph.D. Marin Biologic Laboratories, Inc. +1 4158838000x100 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
19 hours ago
- Associated Press
NAPA Kitchen and Wine Wins Prestigious Wine Spectator Award for a Second Time
RICHMOND, VA / ACCESS Newswire / June 27, 2025 / NAPA Kitchen and Wine, located in Westchester Commons in Midlothian, Virginia, is thrilled to announce it has once again received the Wine Spectator Award of Excellence. This distinguished honor recognizes restaurants with expertly curated wine lists that not only enhance their cuisine but also showcase a thoughtful, diverse selection of top-tier producers from around the Event at NAPA Kitchen and Wine Renowned for its vibrant ambiance and fresh, West Coast-inspired cuisine, NAPA Kitchen and Wine continues to raise the bar for wine and dining experiences in the Midlothian area. With a dynamic wine program that evolves with the seasons, the restaurant emphasizes education, pairing, and guest engagement, making it a must-visit destination for wine enthusiasts and culinary explorers alike. We are incredibly honored to receive this recognition again from Wine Spectator. It's a testament to the passion our team brings to creating an exceptional wine list and delivering unforgettable experiences. At NAPA, wine is more than just something you drink-it's a journey, a story, and a connection. - Dennis Barbaro, Founder & CEO NAPA's award-winning wine list features more than 200 selections from both iconic and emerging regions, with a special focus on Napa Valley and California producers. Guests can enjoy wines by the glass, bottle, or through guided tasting experiences designed to educate and inspire. For those looking to take their wine experience to the next level, the NKW Wine Club offers members exclusive access to limited-release bottles, curated selections from around the world, a first look at private tasting events, and special perks at the restaurant. It's the perfect way for wine lovers to deepen their appreciation and enjoy hand-picked discoveries, all year round. For more information, to join the wine club, or to make a reservation, visit or call (804) 893-5684. Contact Information Lauren Barbaro Chief Creative Officer [email protected] 804-545-2498 ext. 3 SOURCE: DJB Hospitality press release
Miami Herald
19 hours ago
- Miami Herald
Epique Realty Unveils EpiqueAI 2.0 - Thinking Outside the Chatbox
NASHVILLE, TN / ACCESS Newswire / June 26, 2025 / In a highly anticipated keynote at PowerCON 2025, CEO and Co-Founder Joshua Miller, the original architect of Epique's award-winning technology, unveiled the next leap forward: EpiqueAI 2.0. This bold evolution of the proprietary AI platform is designed to move beyond simple automation and serve as a strategic partner for every agent. "The first wave of AI was about handling simple tasks. That's yesterday's news," Miller declared to the energized audience. "EpiqueAI 2.0 is about amplification. It's about making our agents smarter, more creative, and more strategic. We're not giving you a better chatbox; we're giving you an on-demand business partner that lives in your pocket. We didn't just think outside the box-we've deleted the box entirely." Building on the success of industry-leading tools like AIPRO, Virtual Staging, and the fan-favorite Sound Smarter tool, EpiqueAI 2.0 introduces a new suite of groundbreaking features: BrokerAI: Now smarter, faster, and more intuitive, providing instantaneous, expert-level answers to your most complex real estate Coaches: Move beyond generic advice with on-demand, personalized business coaching in real-time to sharpen your skills and game-plan your next 2.0: Your upgraded Epique Real Estate Intelligence Quotient, now with enhanced market insights, predictive analytics, and AI-generated action plans to help you dominate your market. EpiqueAI 2.0 is a testament to the company's philosophy of building technology that doesn't just support agents but empowers them to reach new heights of success. Welcome to the future of real estate. Powered by AI. Built by Epique. About Epique RealtyEpique Realty is a trailblazing, agent-first real estate brokerage committed to empowering its agents through a comprehensive suite of free resources and benefits including extraordinary support, award-winning AI technology, and a culture of radical generosity that fuels agent success. By questioning industry norms and putting agents at the center of its universe, Epique is not just transforming the real estate market-it is defining the future. #BeEpique Learn more at Barbara Simpson | PR and Communications 281-773-7842 | Barbara@ SOURCE: Epique Realty
